TUCSON, Ariz., Oct. 6, 2022 — Critical Path Institute (C-Path) today announced that it has recently launched a pre-consortium collaboration […]
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
– Initiates first-in-human trial of next-wave AAT corrector, VX-634 – Phase 2 study evaluating the impact of longer-term treatment with VX-864 to […]
Read More… from Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency